Sector News

Lundbeck names new CEO after first-quarter loss

May 6, 2015
Life sciences
Danish pharmaceutical company H.Lundbeck A/S said Wednesday it had appointed a new chief executive after the company swung into a net loss amid heightened uncertainty during the first quarter.
 
Lundbeck, which has been facing tough competition and a price erosion of some of its mature products, said it had named Kare Schultz as its new president and chief executive officer starting May 20.
 
Prior to joining Lundbeck, Mr. Schultz forged a long career at Lundbeck’s bigger Danish rival, the insulin maker Novo Nordisk A/S NVO, -2.32% where he rose to become the company’s chief operating officer.
 
However, Mr. Schultz resigned from Novo last month when the company’s board decided that Novo’s current CEO Lars Rebien Sorensen should remain in his position for the time being.
 
Lundbeck’s quarterly net loss for the three months through March was 81 million Danish kroner ($12.2 million), compared with a net profit of DKK331 million in the year-earlier period.
 
The net loss figure was precisely the same as the median analyst forecast in a poll carried out by financial data provider SME Direkt.
 
Lundbeck’s quarterly revenue was DKK3.56 billion, slightly down from DKK3.59 billion a year earlier and above a median forecast of DKK3.20 billion.
 
The company said that it is experiencing unusually high uncertainty as it invests in the launch and late-stage development of new products.
 
Lundbeck kept its full-year 2015 guidance unchanged. It is expecting its core revenue to be between DKK13.2 billion and DKK13.7 billion in 2015, compared with DKK13.5 billion in 2014, and its core operating profit to be at zero, down from DKK1.2 billion in 2014.
 
“The outlook reflects constant exchange rates and expectations for continued robust performance of the portfolio of strategic core products which partly offsets the continued generic erosion of mature products,” the company said.
 
By Juhana Rossi 
 
Source: Wall Street Journal via MarketWatch

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]